Chinese experts consensus on treatment-resistant schizophrenia(2025)
10.3969/j.issn.1002-0152.2025.04.001
- VernacularTitle:难治性精神分裂症中国专家共识(2025)
- Author:
Xiangyi MA
1
;
Xiu ZHANG
;
Jingxin XUE
;
Qing KANG
;
Xiangyun LONG
;
Peiyuan TANG
;
Sijia WEI
;
Jiaqi LIU
;
Shenglin SHE
;
Yingjun ZHENG
;
Dengtang LIU
Author Information
1. 上海交通大学医学院附属精神卫生中心(上海 200030)
- Publication Type:Journal Article
- Keywords:
Schizophrenia;
Treatment-resistant schizophrenia;
Treatment-resistant;
Clozapine;
Expert consensus
- From:
Chinese Journal of Nervous and Mental Diseases
2025;51(4):193-210
- CountryChina
- Language:Chinese
-
Abstract:
Schizophrenia is a chronic and debilitating mental disorder.Around 20%to 40%of patients do not respond well to normal antipsychotic medication,and are ultimately diagnosed with treatment-resistant schizophrenia(TRS),representing the most severe and challenging form of schizophrenia.Currently,clozapine is the standard treatment for TRS.Early identification and standardized treatment can be beneficial to patients with TRS by controlling acute-phase symptoms as soon as possible,reducing suicidal rate and improving their quality of life.Under the guidance of the Steering Committee,this consensus was formed after multiple discussions by 30 psychiatric experts and anonymous Delphi surveys including 17 consensus opinions on treatment-resistant schizophrenia,which cover risk factors and prevention,diagnosis and evaluation,standardized clozapine treatment and management of adverse reactions,treatment regimens for clozapine resistance and intolerance,and psychosocial intervention,etc.The consensus-making process also incorporated evidence-based medicine to help standardize and guide diagnosis and treatment for adults with TRS in China.
